Vera Therapeutics (VERA) Short term Debt (2021 - 2023)

Vera Therapeutics' Short term Debt history runs 3 years deep, the most recent figure standing at $3.1 million for Q1 2023.

• Quarterly Short term Debt rose 87.2% year-over-year to $3.1 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $3.1 million (up 87.2% YoY) and the FY2022 annual result came in at $2.8 million, up 172.02% from the prior year.
• Short term Debt was $3.1 million for Q1 2023 at Vera Therapeutics, up from $2.8 million in the prior quarter.
• Across five years, Short term Debt topped out at $3.1 million in Q1 2023 and bottomed at $994000.0 in Q3 2021.
• A 3-year average of $1.7 million and a median of $1.6 million in 2022 frame the typical range for Short term Debt.
• Peak annual rise in Short term Debt reached 172.02% in 2022, while the deepest fall reached 1.01% in 2022.
• Vera Therapeutics' Short term Debt stood at $1.0 million in 2021, then jumped by 172.02% to $2.8 million in 2022, then advanced by 10.43% to $3.1 million in 2023.
• Business Quant data shows VERA's Short term Debt at $3.1 million in Q1 2023, $2.8 million in Q4 2022, and $1.0 million in Q3 2022.